Survodutide's Impact on Common Drug Levels in Overweight or Obese Individuals
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
Background
Survodutide (BI 456906) is a novel GLP-1/glucagon receptor dual agonist being developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). As patients with overweight or obesity often take multiple medications, understanding potential drug-drug interactions is crucial for patient safety and efficacy. This Phase I study specifically aimed to determine if multiple doses of Survodutide influence the blood levels (pharmacokinetics) of commonly co-prescribed drugs like bupropion, caffeine, and midazolam.
Study Design
Population
Overweight or obese individuals taking commonly co-prescribed drugs.
Intervention
Multiple doses of Survodutide (BI 456906), a GLP-1/glucagon receptor dual agonist; dose and route not specified.
Outcome
The primary outcome was to determine if Survodutide influences the blood levels (pharmacokinetics) of bupropion, caffeine, and midazolam.